Last reviewed · How we verify
NCT05285410: OUTREACH
Observational Study Comparing Home to Office Spirometry
trial in Cystic Fibrosis in 116 participants. Completed in 19 December 2023.
19 December 2023
Quick facts
| Lead sponsor | Chris Goss |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 116 |
| Start date | 30 November 2022 |
| Primary completion | 19 December 2023 |
| Estimated completion | 19 December 2023 |
| Sites | 19 locations across United States |
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
Sponsor
Chris Goss — full company profile →
Who can join
6 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, longitudinal multicenter observational study comparing home to office spirometry and home to office weight and height measurements. The aim of the study is to estimate the accuracy and variability of home spirometric measurements over time, and to assess the feasibility and acceptability of home measurements.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
Hisert KB, Birket SE, Clancy JP, Downey DG, et al · · 2023 · cited 47× · PMID 37699420 · DOI 10.1016/s2213-2600(23)00324-7 -
Technology and Human Support Systems in Decentralized Studies: A Participant-Centered Case Study in Cystic Fibrosis.
Sarrieddine A, Lai C, Walk OBD, Reid NFH, et al · · 2024 · PMID 41726402
Verify or expand the search:
- PubMed search for NCT05285410
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other Chris Goss trials
Trials by the same sponsor.
- NCT07312734 — Study to Enable New Diagnostics for Pulmonary Microbes in People With CF · not yet recruiting
- NCT05548283 — Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study · Phase 4 · recruiting
- NCT04294043 — IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) · Phase 1 · recruiting
- NCT03801993 — Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05285410 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chris Goss
- Last refreshed: 11 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05285410.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing